KRAS Allele-Specific Drug Pipeline: G12C, G12D and Beyond
KRAS is not one drug target. G12C created a covalent binding opportunity, G12D requires different chemistry, and multi-selective RAS programmes aim to cover several variants. The pipeline changes quickly, so registry status matters as much as mechanism.
Quick Answer
KRAS is not one drug target. G12C created a covalent binding opportunity, G12D requires different chemistry, and multi-selective RAS programmes aim to cover several variants. The pipeline changes quickly, so registry status matters as much as mechanism.
Side-by-side comparison
Pipeline categories solve different structural and coverage problems; examples are investigational unless an approval is stated in the linked source.
| Approach | Design logic | Important boundary |
|---|---|---|
| KRAS G12C inhibitors | Exploit the cysteine introduced at codon 12 | Do not cover G12D or G12V |
| KRAS G12D inhibitors | Non-covalent or allele-tailored binding | Clinical programmes can change or terminate |
| Multi-selective RAS(ON) inhibitors | Target active-state RAS across selected variants | Coverage and selectivity differ by molecule |
| Upstream combinations | Block feedback through EGFR, SHP2 or SOS1 | Tumour lineage and toxicity shape feasibility |
Why G12C Came First
The G12C substitution introduces a cysteine that can be covalently engaged by small molecules in a switch-II pocket. That chemical handle enabled allele-specific drugs that lock KRAS G12C in an inactive state.
The same strategy cannot simply be copied to G12D because aspartate has different chemistry. Exact allele identity is therefore part of the drug mechanism, not a minor reporting detail.
G12D Requires Different Chemistry
MRTX1133 demonstrated that a potent non-covalent molecule could selectively inhibit KRAS G12D in biochemical and preclinical tumour models. Its study record is also a reminder that promising preclinical rationale does not guarantee a continuing clinical programme: the registered phase 1 study is listed as terminated.
Other G12D programmes are recruiting, including mutation- and tumour-specific studies. Their records should be checked for current status, eligibility and locations rather than inferred from older pipeline lists.
From One Allele to Multi-Selective RAS
Multi-selective programmes try to inhibit active RAS across a defined set of variants or RAS proteins. That could widen coverage beyond a single codon substitution, but 'pan-RAS' and 'multi-selective' are not interchangeable claims.
RMC-6236 is registered in a recruiting phase 1/2 study for solid tumours with specified RAS mutations. Its clinical value remains a trial question, not an established class conclusion.
Feedback and Combination Logic
RAS-pathway inhibition can release negative feedback and increase upstream receptor signalling. EGFR, SHP2 and SOS1 combinations attempt to reduce that adaptive rebound or prevent nucleotide-state cycling.
The relevant combination depends on tumour lineage and allele. Activity observed in lung, colorectal or pancreatic models should not be transferred automatically between diseases.
Key Takeaways
- ·G12C, G12D and G12V are distinct drug-development problems.
- ·A terminated study is informative pipeline data and should not be hidden behind an outdated list.
- ·Live registry status and exact molecular eligibility are essential when following the KRAS pipeline.
Put these genes in pathway context
Frequently asked questions
What is the key idea in KRAS Allele-Specific Drug Pipeline: G12C, G12D and Beyond?
KRAS is not one drug target. G12C created a covalent binding opportunity, G12D requires different chemistry, and multi-selective RAS programmes aim to cover several variants. The pipeline changes quickly, so registry status matters as much as mechanism.
What should be kept with the result or mechanism?
G12C, G12D and G12V are distinct drug-development problems. A terminated study is informative pipeline data and should not be hidden behind an outdated list. Live registry status and exact molecular eligibility are essential when following the KRAS pipeline.
References
- 1Anti-tumour efficacy of the KRAS G12D inhibitor MRTX1133. Nature Medicine, 2022. PubMed
- 2Study of RMC-6236 in RAS-mutant solid tumours. ClinicalTrials.gov, 2026. ClinicalTrials.gov
- 3MRTX1133 study record. ClinicalTrials.gov, 2026. ClinicalTrials.gov
- 4BAY 3771249 KRAS G12D study. ClinicalTrials.gov, 2026. ClinicalTrials.gov
Continue Reading
KRAS G12C vs G12D: Similar Gene, Different Alterations
2 min read
KRAS G12D Mutation: Biology, Testing and Context
2 min read
KRAS G12V Mutation: How to Interpret the Finding
2 min read
KRAS Mutations: Constitutive MAPK Signalling and Targeted Therapy
6 min read
How Sotorasib Works: Locking KRAS G12C in Its Off State
4 min read
Sotorasib vs Adagrasib: Two KRAS G12C Inhibitors Compared
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
KRAS has 300+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.